Physician profile
Carter Cox, JR.
NPI 1386633485
$1,230.11
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $90.78 · 2021: $210 · 2022: $97.83.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $326.84 | 2019-2021 | |
| Novo Nordisk INC | $291.39 | 2019-2021 | |
| Allergan, INC. | $128.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $104.36 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $104.35 | 2019 | |
| Lilly USA, LLC | $97.83 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.13 | 2019 | |
| Pfizer INC. | $73.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.21 | 2021 | |
| Aytu Biopharma, INC. | $12.09 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carter Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.